| Reagan-Udall Foundation

Importantly, on October 1, 2024, the FDA implemented a long-planned reorganization of the Human Foods Program and the FDA field operations in response to the Reagan-Udall Foundation Evaluation published in 2022.

Coverage

Read more about Clinical Leader: Trends In FDA FY 2024 Inspection-Based Warning Letters

Read more about Evaluating the Impact of a Functional and Cognitive Strategy in Patients with Long Covid-19

Read more about Assessment of Vertigo and Dizziness in Individuals Following COVID-19

Read more about Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, As First-line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients with a PD-L1 Combined Positive Score (CPS)≥1≤19.

Subscribe to

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Long-term Symptomatic Follow-up of Patients with Long COVID Syndrome

Physiological and QoL Benefits of Qi-Gong in Post-acute Sequelae of Covid-19

Bedside Assessment of Immune Function in Patients With Covid-19

Infant Malaria Vaccine Schedule Optimization

Vima Therapeutics

Medregen LLC

Clinical Leader: Trends In FDA FY 2024 Inspection-Based Warning Letters

Evaluating the Impact of a Functional and Cognitive Strategy in Patients with Long Covid-19

Assessment of Vertigo and Dizziness in Individuals Following COVID-19

Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, As First-line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients with a PD-L1 Combined Positive Score (CPS)≥1≤19.

Subscribe for updates from the Reagan-Udall Foundation for the FDA